NVS vs TMO
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | NVS | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $156.11 | $574.30 | |
| Market cap as of 2026-08-03 | $232.1B | $212.3B | |
| P/E as of 2026-08-03 | 22.53 | 30.92 | NVS lower |
| PEG as of 2026-08-03 | 3.66 | 3.39 | TMO lower |
| Net margin as of 2026-08-03 | +22.5% | +15.0% | NVS higher |
| Gross margin as of 2026-08-03 | +75.0% | +40.9% | NVS higher |
| Operating margin as of 2026-08-03 | +29.9% | +17.6% | NVS higher |
| ROE as of 2026-08-03 | +29.9% | +13.3% | NVS higher |
| ROA as of 2026-08-03 | +11.1% | +6.3% | NVS higher |
| Debt / equity as of 2026-08-03 | 1.18 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-08-03 | +3.3% | +7.2% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.3% | |
| Dividend yield as of 2026-08-03 | +2.9% | +0.3% | NVS higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-03 | 1.17 | 0.75 | |
| 1-year return as of 2026-07-27 close | +32.6% | +22.8% | NVS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.